

22 June 2026

Biological Treatments for Oncology RCC

I have a freedom of information request regarding the treatment of renal cell carcinoma. Could you please answer the following questions:

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

- Avelumab + Axitinib <5
- Axitinib 0
- Cabozantinib 32
- Everolimus <5
- Lenvatinib + Everolimus 10
- Lenvatinib + Pembrolizumab 7
- Nivolumab monotherapy 11
- Nivolumab + Cabozantinib 27
- Nivolumab + Ipilimumab <5
- Pazopanib 0
- Pembrolizumab monotherapy 27
- Pembrolizumab + Axitinib 0
- Radiotherapy only
- Sunitinib <5
- Temsirolimus 0
- Tivozanib 9
- Other active systemic anti-cancer therapy 0
- Palliative care only not available
- Pembrolizumab (solution for subcutaneous injection) 0

Q2. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments :

- Avelumab + Axitinib (Bavencio + Inlyta) <5 (<5)
- Cabozantinib (Cometriq) 12 (5)
- Nivolumab (Opdivo) 0
- Nivolumab + Cabozantinib (Opdivo + Cometriq) 20 (<5)
- Nivolumab + Ipilimumab (Opdivo + Yervoy) 4 (<5)
- Lenvatinib + Pembrolizumab (Kisplyx + Keytruda) 6 (<5)
- Pembrolizumab + Axitinib 0

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma? :

- Nivolumab (monotherapy) 5

22 June 2026

- Nivolumab + Ipilimumab <5
- Nivolumab + Cabozantinib <5
- Avelumab + Axitinib <5
- Lenvatinib + Everolimus 9
- Lenvatinib + Pembrolizumab (Kispalyx + Keytruda) <5
- Cabozantinib (Cometriq) 12
- Pembrolizumab + Axitinib 0

***Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

In the past 3 months (Mar 26 – May26) the Belfast Trust Urology service has performed 32 partial nephrectomy and 8 total nephrectomy procedures.

Q5. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?

CV6-168

Title: A First-in-Human Modular, Open-label, Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of the specific dUTPase inhibitor CV6-168 in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies.

- 0 renal patients on study.

(The ModiFY Study)

A Phase 1/2, Multicentre, Open-Label Study of Modi-1 Moditope® in Patients with Breast, Head and Neck, Ovarian, or Renal Cancer (The ModiFY Study)

- <5 renal patients on study.

Please note:

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.